Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study

ABSTRACT: Detection of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study

DISEASE(S): Colorectal Cancer,Pancreatic Cancer,Pancreatic Neoplasms

PROVIDER: 2732841 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

The Colorectal Breath Analysis (COBRA) Study

Project description:This study aims to determine whether a breath test could be used for early detection of colorectal cancer and colorectal polyps. Patients who are attending for a planned colonoscopy or who are scheduled to undergo elective resection of histologically confirmed colorectal cancer (adenocarcinoma) will be approached to provide a breath sample. Multi platform mass spectrometry analysis will be performed to establish volatile biomarkers that can discriminate between colorectal cancer, benign colorectal disease (e.g. polyps) and healthy controls.

| 2286292 | ecrin-mdr-crc

Expression analysis of inflammatory cytokines in exhaled breath condensates from pediatric patients with sickle cell disease, asthma, sickle cell disease and asthma, and controls

Project description:To analyze expression of inflammatory cytokines in Exhaled Breath Condensates from pediatric patients with sickle cell disease, asthma, sickle cell disease and asthma, and controls

2020-05-08 | GSE150056 | GEO

Feasibility and clinical utility of whole genome profiling in pediatric and young adult cancers

Project description:Feasibility and clinical utility of whole genome profiling in pediatric and young adult cancers

| PRJNA766101 | ENA

Volatiles in Breath and Headspace Analysis - Diagnostic Markers

Project description:Detection of Volatile Organic Compounds (VOC) directly from tissue by headspace analysis (skin, surgery material, other tissue) and exhaled breath is feasible using affordable user-friendly novel nano-chemo sensors that can accurately be used for screening and monitoring purpose

| 2250131 | ecrin-mdr-crc

Breath Metabolites from Healthy Children

Project description:These are breath samples collected from healthy children

2024-07-15 | MSV000095340 | MassIVE

Phosphoproteomics Data of pancreatic cancers cells treated with anlotinib

Project description:Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials. A comprehensive knowledge of the mechanism of angiogenesis inhibitors against pancreatic cancer is helpful for clinical purpose and for the selection of patients who might benefit from the inhibitors. In this work, multi-omics analyses (transcriptomics, proteomics and phosphoproteomics profiling) were carried to delineate the mechanism of anlotinib, a novel angiogenesis inhibitor, against pancreatic cancer cells.

2021-09-09 | PXD023345 | Pride

COlorectal BReath Analysis (COBRA2)

Project description:Colorectal cancer (CRC) is the second most common cause of cancer death in the United Kingdom, with approximately 17,000 deaths per year. The five-year survival rate from CRC is only 10% when discovered at a late stage, but exceeds 90% if diagnosed early. Symptoms related to CRC can be non-specific, therefore the decision to refer for a colonoscopy can be challenging. There is a clear need to improve earlier detection of CRC so that patients with CRC can be identified earlier and faster, enabling them to start treatment more quickly. The study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that are specific to CRC. For patients with non-specific symptoms, this test would help GPs to identify those patients that may have underlying CRC, who would benefit from referral for specialised CRC tests.

| 58988 | ecrin-mdr-crc

Personalised therapeutic management of epileptic patients guided by pathway-driven breath metabolomics

Project description:BACKGROUND: Therapeutic management of epilepsy remains a challenge, since optimal systemic antiseizure medication (ASM) concentrations do not always correlate with improved clinical outcome and minimal side effects. We tested the feasibility of non-invasive real-time breath metabolomics as an extension of traditional therapeutic drug monitoring for patient-stratification by simultaneously monitoring drug-related and drug-modulated metabolites.METHODS: This proof-of-principle observational study involved 93 breath measurements of 54 paediatric patients monitored over a period of 2.5 years, along with an adults’ cohort of 37 patients measured in two different hospitals. Exhaled breath metabolome of epileptic patients was measured in real-time using secondary electrospray ionization-high resolution mass spectrometry (SESI-HRMS).RESULTS: We show that systemic ASM concentrations could be predicted by the breath test. Total and free valproic acid (VPA; an ASM) is predicted with concordance correlation coefficient (CCC) of 0.63 and 0.66, respectively. We also find i) high between- and within-subject heterogeneity in VPA metabolism; ii) several amino acid metabolic pathways are significantly enriched (p < 0.01) in patients suffering from side effects and iii) tyrosine metabolism is significantly enriched (p < 0.001), with downregulated pathway compounds in non-responders.CONCLUSIONS: These results show that real-time breath analysis of epileptic patients provides reliable estimations of systemic drug concentrations along with risk estimates for drug response and side effects.

2021-06-21 | MTBLS2400 | MetaboLights

Pulmonary parasite infection: do trypanosomes take your breath away?

Project description:Pulmonary parasite infection: do trypanosomes take your breath away?

| PRJNA876276 | ENA

Preparing for the first breath at single cell level

Project description:Preparing for the first breath at single cell level

| PRJNA504641 | ENA